Akebia Therapeutics (AKBA) Invested Capital (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Invested Capital data on file, last reported at $76.3 million in Q1 2026.

• Invested Capital for Q1 2026 came in at $76.3 million, up 7.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $76.3 million (up 7.28% YoY), and the FY2025 annual result was $80.9 million, up 870.68% from the prior year.
• Invested Capital fell to $76.3 million in Q1 2026 per AKBA's latest filing, from $80.9 million in the prior quarter.
• Over five years, Invested Capital peaked at $157.1 million in Q2 2022 and troughed at -$31.4 million in Q3 2023.
• A 5-year average of $45.7 million and a median of $71.1 million in 2025 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2024 and 2025: Invested Capital sank 355.96% in 2024, then jumped 2362.49% in 2025.
• A 5-year view of Invested Capital shows it stood at $71.3 million in 2022, then plunged by 94.25% to $4.1 million in 2023, then tumbled by 355.96% to -$10.5 million in 2024, then jumped by 870.68% to $80.9 million in 2025, then fell by 5.68% to $76.3 million in 2026.
• Business Quant data shows AKBA's Invested Capital at $76.3 million in Q1 2026, $80.9 million in Q4 2025, and $89.2 million in Q3 2025.